Practical Guidance on Mental Health and Physician Burnout
Latest News
New ASCO Guidelines Offer A Practice-Changing Approach For PIK3CA/AKT1/PTEN Metastatic Breast Cancer
ASCO Rapid Recommendation Update: Combining capivasertib with fulvestrant enhances PFS in metastatic breast cancer, ushering in personalized treatment options.
Learn MoreAn Evidence-Based Approach to Discussing Clinical Trials WIth Your Patients
A physician checklist can help ease the difficulty of discussing clinical trial participation with patients who are not responding to current treatment.
Learn MoreStudy: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates
A new study underscores the importance of weight counseling in breast cancer. Gains and losses are associated with lower chance of survival, especially in patients who undergo chemotherapy.
Learn MoreStudy Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care
New Yale study finds a significant rise in the use of immunotherapy in late-stage cancer, highlighting its growing use in end-of-life care and a greater success rate at larger institutions.
Learn MoreNearly 50% Skip Prescribed Breast Cancer Meds; Physicians Should Focus On Cost Cutting and Education
A new study suggests that cost-reduction policies and targeted interventions significantly increase adjuvant endocrine therapy adherence among breast cancer survivors.
Learn MoreCriteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma
FDA grants accelerated approval for lifileucel, a TIL therapy for advanced melanoma, marking a first for a cellular therapy targeting a solid tumor.
Learn MorePhysicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval
Rybrevant receives FDA approval as a game-changing treatment for NSCLC with specific genetic mutations, marking a significant advancement in personalized cancer therapy.
Learn MoreElahere Has Become A Practice-Changing Option for Platinum-Resistant, FRα Ovarian Cancer
FDA-approved Elahere for FRα-positive, platinum-resistant ovarian cancer offers new hope with its targeted mechanism and positive trial results.
Learn More